Although written by someone on behalf of Alto Capital (raised funding for them) in the latest Bull Newsletter they like me think obviously like it. Personally believe this is one of the best risk/reward biotechs on the ASX. I have the largest holding in this one of all my biotechs. If they manage to successfully use exosomes from person to person it will be IMO like a Cochlear/ CSL:
This biopharmaceutical company is focusing on regenerative medicines. It’s seeking to develop and commercialise exosomes as therapeutic agents. According to EX1, an objective of testing exosome-based therapies is to develop new ways to tackle medical conditions afflicting people in old age. Senior management is highly experienced. EX1 offers potential, but as a biopharmaceutical company it carries risk. A speculative buy for those with a suitable risk appetite.
EX1 Price at posting:
41.5¢ Sentiment: Buy Disclosure: Held
